Magnetic resonance spectroscopy (MRS) is a non-invasive in vivo method that allows the investigation of biochemical changes in both animals and humans. The application of MRS to the study of stroke has made possible dynamic studies of intracellular metabolism of cerebral ischaemia. The majority of the stroke studies have been carried out using proton [ 1 H]-MRS which allows the detection of N-acetyl aspartate (NAA), a neuronal marker. ['H]-MRS changes in humans demonstrate that after an infarct, lactate appears, while NAA and total creatine are reduced compared to the contralateral hemisphere. Longitudinal studies demonstrate a further reduction of NAA suggesting that ischaemic injury continues for more than a week following infarction.
Conventional magnetic resonance imaging (MRI) is a well-developed and much utilised method for visualising the radiological extent of disorders involving cerebral ischaemia. Magnetic resonance spectroscopy (MRS) is a non-invasive in vivo method that allows the investigation of biochemical changes in both animals and humans. The application of MRS to the study of stroke has made possible dynamic studies of intracellular metabolism of cerebral ischaemia. The concentrations of metabolites detected by MRS are relatively low (2-20 mM) compared to the concentration of water (83.4 M) detected by MRI, and the sensitivity to local magnetic field inhomogeneities and difficulties in quantitation of peak areas has until recently limited the technique to use as a research tool. Despite the relatively low signal-tonoise ratio of spectroscopy, improvements in magnet and gradient design, and the wider availability of magnets at high field strength (1.5 T) now enable good quality brain [ ] H]-MRS spectra to be recorded on most modern clinical instruments.
['HJ-MRS and phosphorus [ tissue contains hydrogen. The study of cerebral ischaemia in humans is predominantly confined to PHJ-MRS, the subject of this chapter. Until recently, data acquisition required the skills of experienced spectroscopists and physicists for manual adjustment of parameters for each and every scan resulting in long examination times. The development of automated software programs, like the single voxel proton brain exam (PROBE, General Electric, Milwaukee, USA) 1 , and their implementation on clinical systems has gone a long way to overcoming some of the problems of data collection. The small concentrations of visible metabolites requires the collection of data from a single voxel many times larger than that required for MR imaging.
Chemical shift imaging (CSI) or multivoxel MR spectroscopic imaging is a more advanced form of spectroscopy that uses phase encoding to subdivide a large volume of interest into smaller acquisition voxels, thereby allowing the study of large and heterogeneous areas of brain. The major disadvantages of CSI include complicated acquisition techniques, longer scan times, and a large volume of generated data. CSI is ideally suited to the study of stroke, particularly in the detection of the ischaemic penumbra. However, the complexity of image acquisition and data processing often necessitates the availability of a dedicated spectroscopist and has Limited the number of stroke studies carried out using CSI.
The normal [

H]-MRS spectrum
Histochemical and cell culture studies have shown that specific cell types or structures have metabolites that give rise to ['HJ-MRS peaks. A change in the resonance intensity of these marker compounds may reflect loss or damage to a specific cell type or compound.
The acquisition of long echo data (TE = 270 ms, TR = 3 s) only allows the detection of NAA, Cr/PCr and Cho in normal brain, and lactate in regions of abnormality. T 2 losses results in lower signal-to-noise and increases the complexity of quantitation methods. The acquisition of short echo time data (TE = 30 ms, TR = 2s) reduces the effects of signal loss due to T 2 relaxation and, therefore, provides spectra with increased signal-to-noise. In addition, short echo time spectroscopy detects additional resonances from metabolites with complex MR spectra such as myo-inositol, glutamate and glutamine. Signals from these metabolites cancel at long echo times due to phase modulation ('J-couphng'). Whilst providing us with more information, short echo time data include a broad background signal consisting of low concentration metabolites, and macromolecules and lipids with short T 2 relaxation times, which increases the difficulty of accurate peak area estimation. Short echo ['ITJ-MRS spectra acquired from an infarct and the contralateral hemisphere are shown in Figure 1 . The chemical shift of the peaks are assigned with respect to water which has been removed from the spectra.
N-acetyl aspartate (2.01 ppm)
The methyl resonance of N-acetyl aspartate (NAA) produces a large sharp peak at 2.01 ppm and acts as a neuronal marker as it is almost exclusively confined to neurones in the human brain, where it is found predominantly in the axons and nerve processes 2 . It has also been found in the oligodendrocyte type II astrocyte progenitor cells in rats 3 , but these cells represent only 2-3 % of the glial population in man 4 . Since the discovery of NAA in 1956 2 , there has been a large body of literature on the synthesis, distribution and function, which has been reviewed by Birken and Oldendorf 5 and Williams 6 . However, despite a large body of work, the function of NAA remains unknown.
The interpretation of NAA signal in the brain of children is complicated by increases in the concentration during development 7 when it is thought to have a role in supplying acetyl groups for myelin synthesis 6 . In adults, the concentration of NAA is known to vary in different areas of the brain 8 . This can be overcome in the study of stroke patients by using the contralateral hemisphere for comparison 9 .
Creatine (3.94 & 3.03 ppm)
Both creatine and phosphocreatine have signals at 3.94 ppm (methylene singlet) and 3.03 ppm (methyl singlet) which makes it impossible to distinguish between the two compounds and therefore total creatme (Cr/PCr) signal changes are considered by PHJ-MRS. Other resonances seen at 3.03 ppm arise from y-amino butyric acid (GABA) 10 and cytosolic macromolecules become incorporated into the Cr/PCr peak 11 -12 . Cr/PCr is found in both neurones and glial cells 4 and acts as a phosphate transport system and energy buffer within the cell. As the signal comes from the sum of creatine and phosphocreatine, little information can be gleaned about phosphocreatine metabolism. The complete absence of creatine signal probably reflects necrotic tissue, but the interpretation of reduced total creatine levels requires more work.
Choline (3.22 ppm)
The trimethylamine resonance of choline-containing compounds is present at 3.2 ppm and has been proposed as a marker of membrane damage.
Stroke
In normal brain, the choline (Cho) peak is thought to consist predominantly of glycerolphosphocholine and phosphocholine; both compounds are involved in membrane synthesis and degradation 13 .
Lipid/macromolecule resonances
Lipid peaks are detectable by short echo proton spectroscopy but not seen at long echo due to T 2 losses. Peaks assigned to lipids/macromolecules have been detected at 0.9, 1.3 and 1.45 ppm in normal appearing brains 14 ' 15 . Increases in these peaks have been reported in stroke 15 , and demyelination 14 -16 . The 0.9 and 1.3 ppm resonances are assigned to the methylene and methyl groups of lipid, respectively 17 . Recent work in animal models has shown that contributions to these resonances also arise from mobile proteins 12 , and correlate with peaks found in humans 18 . The significance of the appearances of these peaks is as yet unknown and may only represent increased MRS visibility of cell membrane lipids following cell breakdown. The assignment of these signals will, however, influence the interpretation of proton spectra obtained from the cerebral cortex. Lactate is not normally detected within the brain and, as the end product of glycolysis, is a particularly useful measure of metabolism. The concentration of lactate rises when the glycolytic rate exceeds the tissue's capacity to catabolise it or remove it from the blood stream. The rise in brain lactate that results from the mismatch between glycolysis and oxygen supply has been demonstrated by numerous [ . Removal of lactate depends on tissue perfusion, the permeability of the blood brain barrier (BBB) and diffusion of the metabolite through the damaged tissue. The fall of lactate concentration has been shown to occur during a period of hyperaemia 20 . Using [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] C]-labelled glucose, the metabolic activity of the lactate pool associated with a 32-day-old stroke has demonstrated that all the cerebral lactate arises from glycolysis of serum glucose. This supports the hypothesis that elevated lactate, present weeks after a stroke, is the product of ongoing lactate synthesis in the brain 21 . It is not possible to establish whether the lactate is being produced by on-going ischaemic tissue or metabolically active macrophages. The presence of lactate beyond the time in which active phagocytosis occurs supports the theory of persistently ischaemic tissue 22 . Spectroscopic imaging studies have demonstrated that lactate levels in regions adjacent to the T 2 hyperintensities were not significantly different from those found in the infarcted brain and that lactate is not confined to areas of infarction determined by T 2 -weighted imaging and were even found in the contralateral hemisphere in patients with large infarcts 23 .
NAA (2.01 ppm)
Longitudinal studies in humans demonstrated a decline in NAA following initial reductions in NAA detected in the first spectra after the onset of cerebral infarction . The continuing fall in NAA concentration over the course of the first week after stroke onset cannot be explained simply by an increase in oedema because changes in the concentration of water within the infarct have been corrected for by using the contralateral water signal as the internal standard 9 . It has been suggested that NAA is actively degraded by enzymes within the injured neurones in the first few days or hours following infarction 16 . This remains a possibility, but it would appear unlikely that enzymes would remain active for up to 7-10 days within an ischaemic neurone. The gradual decline in NAA concentration and the persistence of lactate within the region of infarction over a period of a number of days is suggestive of ongoing ischaemia 9 ( Fig. 2) and has important implications in the timing of therapeutic intervention.
Cr/PCr (3.94 & 3.03 ppm) Initial reductions in Cr/PCr are identified following infarction and further reductions have been demonstrated up to 10 days following the time of onset 9 . The reduction in NAA in the infarct region is more marked than the reduction in Cr/PCR and this is thought to reflect the increased sensitivity of neurones to ischaemia. weeks following infarction. Lactate is visible within 16 h and persists for 6 weeks The lactate peaks can be seen to increase further with some contribution from underlying lipids. Choline increases up to 6 weeks which reflects increased visibility of choline containing compounds within the membrane due to cell necrosis, (see Fig. 1 for peak assignments). . The changes in the choline peak are thought to reflect changes in the MR visibility of the choline containing compounds that make up the cell membrane.
Glutamate and other amino acids
Measurements of amino acids, such as glutamate and glutamine, are difficult due to their complex peak structures. Other amino acids, such as GABA, aspartate and alanine are difficult to detect because of their low concentration and/or overlap with more intense resonances from other 4 weeks following stroke onset The top spectrum is the 'standard' spectrum showing a large lipid peak underlying the asymmetrical peaks of the lactate doublet The centre spectrum is the metabolite 'nulled' spectrum acquired from underlying lipid/macromolecules and showing a large lipid peak at the position of the lactate peak (1.3 ppm). The bottom spectrum is the 'pure' metabolite or 'difference' spectrum and shows the lactate signal as a doublet without the underlying baseline. NAA = N-acetyl aspartate, Cr/PCr = total creatine, Cho = choline, Lac = lactate, L1 and L2 = lipids, MM = macromolecule peak.
standard" c)
"I ppm compounds 24 . To date, there is very little work in cerebral ischaemia on the detection of glutamate and glutamine, reflecting the difficulty of spectral analysis.
Lipid/macromolecules
Signals from lipids pose particular problems in ['H]-MRS by obscuring the resonance from the methyl group of lactate. It has been postulated that membrane lipids in the brain under normal conditions are not mobile enough to generate sharp peaks in in vivo spectra. During ischaemia, degradation of the membrane leads to the release of free fatty acids that produce well defined but broad resonances in the region of the Stroke lactate peak resulting in difficulties in the accurate quantitation of lactate. The metabolite nulling technique has been used to separate the lipid from the lactate signal (Fig. 3 , and mitochondrial encephalopathy with lactic acidosis and stroke-like episodes (MELAS) 25 . No convincing reports of reversible NAA in cerebral infarction have been published. In MELAS, the primary defect is mitochondrial and, as NAA is synthesised in mitochondria, it has been suggested that in demyelinating lesions, the function of the mitochondria is reversibly impaired during inflammation resulting in the reversible reduction of the production of NAA within the damaged neurone 14 . CSI studies have observed high levels of lactate return to undetectable levels, in normal appearing regions of the brain separate from the area of infarction. Although, slight reductions in NAA were later observed, the presence of high lactate concentrations did not result in complete infarction 23 .
Quantitation methods in
To move MRS further into the clinical domain and allow the comparison of metabolite concentrations within and between institutions, automated methods of quantitation need to be implemented to provide data analysis protocols for clinical studies. Previously, peak area metabolite ratios calculated from long echo time spectra were used to study metabolic changes in both animal and man. Ratios can be misleading when metabolite concentrations in the numerator and denominator change in disease states. Although the majority of stroke studies have been carried out using metabolite ratios, some studies have used absolute quantitation of brain metabolites 915 . The accuracy of the metabolite estimation depends on the fitting of the accuracy of the fitting method. Various fitting routines have been incorporated in the frequency domain 26 (the conventional domain of MRS data analysis) and the time domain to overcome the problem of contributions to peak area estimates from the underlying baseline and adjacent peaks to improve the accuracy of metabolite quantitation 27 ' 28 . 'Metabolite nulling' has been employed to simplify the spectrum and overcome the problems of the incorporation of the broad background signal into the peak area estimates of short echo proton spectroscopy 18 .
[
H]-MRS as a predictor of outcome
Major advances in the treatment of acute stroke require the accurate prediction of the mortality of stroke patients and, therefore, the identification of patients likely to benefit from drug treatment. Single voxel and CSI studies of stroke have attempted to provide information about the possible outcome of stroke.
Infarct volume determined by T 2 -weighted MR imaging has been shown to be a good predictor of outcome. All patients with small infarcts (<80 cm 3 ) survived 3 months 29 . The addition of the NAA concentration to infarct volume allows a better prediction of patients' morbidity, than either the NAA concentration or infarct volume alone 30 . In a small number of serially studied patients, the best recovery was seen in those patients with relatively preserved NAA, total creatine and choline peaks 31 . Large cerebral infarcts have been shown to be associated with reduced NAA concentration and raised lactate as well as reduced blood velocity. The best predictor of outcome was infarct volume and not metabolite concentration alone 32 . The importance of lactate in the pathogenesis of cerebral infarction has been studied extensively in animals. The degree and extent of tissue damage has been correlated with the content of lactic acid in animals 33 , and an increase in morbidity and mortality m hyperglycaemic animals has been linked to excessive lactate production and the resulting acidosis 34 . The correlation of lactate with outcome in humans, has been variable. Although a single study has shown lactate to correlate with acute stroke severity and outcome 19 , other studies have failed to demonstrate a relationship between outcome and infarct lactate concentration alone 35 . The ability of multivoxel chemical shift imaging to detect changes throughout the brain makes it the most suited spectroscopy technique for the study of cerebral ischaemia. Further development of the CSI and data processing techniques are required to move the use of spectroscopy further into the clinical domain.
